Life Science Intelligence (LSI; Huntington Beach, CA, USA) market analysts reported how growth is most robust in Asia, where total device sales are expected to grow by 14.7% annually and reach $675 million by 2014. While Western Europe has a mature market for breast cancer detection and therapeutic products, Eastern and Southern Europe, as well as most of Asia, are expected to present significant opportunities due to the adoption of the Western lifestyle driving the incidence of breast cancer and the rising standard of living increasing healthcare expenditures.
The report analyzed the markets for breast care detection devices, including products used for mammography, magnetic resonance imaging (MRI), breast-specific gamma imaging (BSGI), and other high-end contrast-based imaging systems. Furthermore, the market includes interventional breast care devices, including the family of biopsy tools (vacuum-assisted, spring-loaded, and large-volume) and minimally invasive breast brachytherapy products.
Although breast cancer is the most common cancer in women, it can be a curable disease, with early detection as the key to survival. Certain companies have already recognized U.S. and Western Europe opportunities and are planning to modify their offerings to the emerging markets of Europe and Asia, where competition will arise from suppliers of low-cost and refurbished systems.
LSI provides market data and competitive intelligence to medical technology executives, entrepreneurs, and investors. LSI produces the EMT (emerging medical technologies) Database, medtech market reports, and provides global custom research services, including market assessments and physician surveys.
Related Links:
Life Science Intelligence
